Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05263206 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
A Phase 3 study of Pruritus, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 284
- Enrollment target
- 20
- Study locations
NCT05263206: Recruiting Phase 3 study of Pruritus, sponsored by Sanofi.
NCT05263206 is a Phase 3 study of Pruritus that is actively recruiting participants, run by Sanofi. The registered enrollment target is 284 participants, above the 87-participant average among 12 other Pruritus trials with a reported enrollment target (226% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05263206, a Phase 3 study of Pruritus, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 284 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objective of the study is to assess efficacy and safety of dupilumab given up to 24 weeks in adults with CPUO. This is a master protocol which includes 2 parallel-treatment, double-blind, 2- arm Phase 3 staggered studies of similar design (Study A and Study B) in male and female participants aged 18 to 90 years with CPUO. Study B design was to be adapted based on the results of Study A. For both Study A and B, after an up-to-4-week screening period, participants with severe pruritus (worst-itch numerical rating scale \[WI-NRS ≥7) will enter a 4-week run-in period and will be treated with a non-sedative antihistamine and an emollient (moisturizer). Participants with severe pruritus (WI-NRS ≥7) at baseline will be randomized (1:1) to be treated for 24 weeks with either dupilumab or matching placebo in addition to their non-sedative antihistamine and emollient regimen. The treatment period for both study A and B will be followed by a 12-week follow-up period.
Primary Outcome
WI-NRS is a patient reported outcome (PRO) comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch").
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dupilumab
- DRUG Fexofenadine (loratadine if not available)
Study Locations (20)
California
- Kern Allergy and Medical Research- Site Number : 8400016 - Bakersfield
- Modena Allergy + Asthma- Site Number : 8400038 - La Jolla
Florida
- Palm Harbor Dermatology- Site Number : 8400024 - Belleair
- University of Miami Hospital- Site Number : 8400011 - Miami
Georgia
- Skin Care Physicians of Georgia - Macon- Site Number : 8400030 - Macon
- Aeroallergy Research Laboratory- Site Number : 8400036 - Savannah
South Carolina
- Columbia Dermatology & Aesthetics- Site Number : 8400047 - Columbia
- National Allergy and Asthma - North Charleston - Northside Drive- Site Number : 8400032 - North Charleston
Santa Fe Province
- Investigational Site Number : 0320004 - Rosario
- Investigational Site Number : 0320008 - Rosario
District of Columbia
- FoxHall Dermatology- Site Number : 8400042 - Washington D.C.
Indiana
- Dawes Fretzin Clinical Research- Site Number : 8400007 - Indianapolis
Kentucky
- Dermatology Specialists Research (DS Research) - Kentucky- Site Number : 8400031 - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 284 participants |
| Start Date | 2022-02-15 |
| Est. Completion | 2027-08-25 |
| Phase | Phase 3 |
What NCT05263206 shows while recruiting
NCT05263206 is an interventional study that assigns participants to a tested intervention. The registered 284 participants enrollment target is mid-sized for trials with a published cap, above the 87-participant average among 12 other Pruritus trials with a reported enrollment target (226% higher).
The record links to 1 condition, with Pruritus appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05263206 names 20 study sites across 15 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT05263206 about?
NCT05263206 is a clinical study titled "Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)". The main objective of the study is to assess efficacy and safety of dupilumab given up to 24 weeks in adults with CPUO. This is a master protocol which includes 2 parallel-treatment, double-blind, 2- arm Phase 3 staggered studies of similar design (Study A and Study B) in male and female participan...
What is the current status of trial NCT05263206?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 284 participants. The study started on 2022-02-15. Estimated completion is 2027-08-25.
What conditions does trial NCT05263206 study?
This clinical trial studies the following conditions: Pruritus.
What interventions are being tested in trial NCT05263206?
The interventions under investigation include: Placebo (DRUG), Dupilumab (DRUG), Fexofenadine (loratadine if not available) (DRUG).
Who is sponsoring clinical trial NCT05263206?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05263206 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pruritus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05263206's enrollment target sits among peer trials
284 2nd of 12 the highest of 12 other Pruritus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pruritus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gabapentin to Treat Itch in Patients With Liver Disease
COMPLETED · Phase 3
-
The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
RECRUITING · NA
-
VR-PMR for Post-Burn Symptoms
RECRUITING · NA
-
Cervical Traction to Reduce Gabaergic Medication Use for Neuropathic Itch
RECRUITING · NA
-
Defining N-Acetyl Cysteine as a Treatment for Inhibiting Prurogenic Stimuli
COMPLETED · Early Phase 1
-
Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05769218 · 284 participants · NA
PrEP and MOUD Rapid Access for Persons Who Inject Drugs: The CHORUS+ Study
- NCT06856577 · 284 participants · Phase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
- NCT06963034 · 284 participants · Phase 3
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- NCT07105098 · 284 participants · Phase 3
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI